Diabetes Symposium Evaluation - October 13, 2018

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree NA=Not applicable to my practice

	5	4	3	2	1	NA
The information and/or skills learned will enhance my professional competence or ability.	The information and/or skills learned will enhance my professional competence or ability. - 5	The information and/or skills learned will enhance my professional competence or ability. - 4	The information and/or skills learned will enhance my professional competence or ability. - 3	The information and/or skills learned will enhance my professional competence or ability. - 2	The information and/or skills learned will enhance my professional competence or ability. - 1	The information and/or skills learned will enhance my professional competence or ability. - NA
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - NA

As a result of participating in this course, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree NA=Not applicable to my practice

	5	4	3	2	1	NA
Define PDE5 inhibitor failure in the diabetic patient.	Define PDE5 inhibitor failure in the diabetic patient. - 5	Define PDE5 inhibitor failure in the diabetic patient. - 4	Define PDE5 inhibitor failure in the diabetic patient. - 3	Define PDE5 inhibitor failure in the diabetic patient. - 2	Define PDE5 inhibitor failure in the diabetic patient. - 1	Define PDE5 inhibitor failure in the diabetic patient. - NA
Utilize clinical principles and expert opinions to evaluate patients with erectile dysfunction.	Utilize clinical principles and expert opinions to evaluate patients with erectile dysfunction. - 5	Utilize clinical principles and expert opinions to evaluate patients with erectile dysfunction. - 4	Utilize clinical principles and expert opinions to evaluate patients with erectile dysfunction. - 3	Utilize clinical principles and expert opinions to evaluate patients with erectile dysfunction. - 2	Utilize clinical principles and expert opinions to evaluate patients with erectile dysfunction. - 1	Utilize clinical principles and expert opinions to evaluate patients with erectile dysfunction. - NA
Describe the surgical treatment options for men with erective dysfunction.	Describe the surgical treatment options for men with erective dysfunction. - 5	Describe the surgical treatment options for men with erective dysfunction. - 4	Describe the surgical treatment options for men with erective dysfunction. - 3	Describe the surgical treatment options for men with erective dysfunction. - 2	Describe the surgical treatment options for men with erective dysfunction. - 1	Describe the surgical treatment options for men with erective dysfunction. - NA
Develop a consistent approach to initiating insulin in the hospital.	Develop a consistent approach to initiating insulin in the hospital. - 5	Develop a consistent approach to initiating insulin in the hospital. - 4	Develop a consistent approach to initiating insulin in the hospital. - 3	Develop a consistent approach to initiating insulin in the hospital. - 2	Develop a consistent approach to initiating insulin in the hospital. - 1	Develop a consistent approach to initiating insulin in the hospital. - NA
Appropriately adjust insulin therapy to accommodate special situation in hospitalized patients with hyperglycemia.	Appropriately adjust insulin therapy to accommodate special situation in hospitalized patients with hyperglycemia. - 5	Appropriately adjust insulin therapy to accommodate special situation in hospitalized patients with hyperglycemia. - 4	Appropriately adjust insulin therapy to accommodate special situation in hospitalized patients with hyperglycemia. - 3	Appropriately adjust insulin therapy to accommodate special situation in hospitalized patients with hyperglycemia. - 2	Appropriately adjust insulin therapy to accommodate special situation in hospitalized patients with hyperglycemia. - 1	Appropriately adjust insulin therapy to accommodate special situation in hospitalized patients with hyperglycemia. - NA
Describe the mechanism of action by which diabetes mellitus (DM) can cause atherosclerotic coronary artery disease.	Describe the mechanism of action by which diabetes mellitus (DM) can cause atherosclerotic coronary artery disease. - 5	Describe the mechanism of action by which diabetes mellitus (DM) can cause atherosclerotic coronary artery disease. - 4	Describe the mechanism of action by which diabetes mellitus (DM) can cause atherosclerotic coronary artery disease. - 3	Describe the mechanism of action by which diabetes mellitus (DM) can cause atherosclerotic coronary artery disease. - 2	Describe the mechanism of action by which diabetes mellitus (DM) can cause atherosclerotic coronary artery disease. - 1	Describe the mechanism of action by which diabetes mellitus (DM) can cause atherosclerotic coronary artery disease. - NA
Explain the association between DM, cardiovascular disease (CVD) and A1C levels.	Explain the association between DM, cardiovascular disease (CVD) and A1C levels. - 5	Explain the association between DM, cardiovascular disease (CVD) and A1C levels. - 4	Explain the association between DM, cardiovascular disease (CVD) and A1C levels. - 3	Explain the association between DM, cardiovascular disease (CVD) and A1C levels. - 2	Explain the association between DM, cardiovascular disease (CVD) and A1C levels. - 1	Explain the association between DM, cardiovascular disease (CVD) and A1C levels. - NA
Discuss the relationship between DM and diabetic cardiomyopathy.	Discuss the relationship between DM and diabetic cardiomyopathy. - 5	Discuss the relationship between DM and diabetic cardiomyopathy. - 4	Discuss the relationship between DM and diabetic cardiomyopathy. - 3	Discuss the relationship between DM and diabetic cardiomyopathy. - 2	Discuss the relationship between DM and diabetic cardiomyopathy. - 1	Discuss the relationship between DM and diabetic cardiomyopathy. - NA
Describe the mechanisms linking DM, obesity and CVD.	Describe the mechanisms linking DM, obesity and CVD. - 5	Describe the mechanisms linking DM, obesity and CVD. - 4	Describe the mechanisms linking DM, obesity and CVD. - 3	Describe the mechanisms linking DM, obesity and CVD. - 2	Describe the mechanisms linking DM, obesity and CVD. - 1	Describe the mechanisms linking DM, obesity and CVD. - NA
Describe the prevalence of diabetic nephropathy and recognize its role as a major contributor to end-stage kidney disease in the U.S.	Describe the prevalence of diabetic nephropathy and recognize its role as a major contributor to end-stage kidney disease in the U.S. - 5	Describe the prevalence of diabetic nephropathy and recognize its role as a major contributor to end-stage kidney disease in the U.S. - 4	Describe the prevalence of diabetic nephropathy and recognize its role as a major contributor to end-stage kidney disease in the U.S. - 3	Describe the prevalence of diabetic nephropathy and recognize its role as a major contributor to end-stage kidney disease in the U.S. - 2	Describe the prevalence of diabetic nephropathy and recognize its role as a major contributor to end-stage kidney disease in the U.S. - 1	Describe the prevalence of diabetic nephropathy and recognize its role as a major contributor to end-stage kidney disease in the U.S. - NA
Recognize the clinical manifestations leading to the development and stage progression of diabetic nephropathy.	Recognize the clinical manifestations leading to the development and stage progression of diabetic nephropathy. - 5	Recognize the clinical manifestations leading to the development and stage progression of diabetic nephropathy. - 4	Recognize the clinical manifestations leading to the development and stage progression of diabetic nephropathy. - 3	Recognize the clinical manifestations leading to the development and stage progression of diabetic nephropathy. - 2	Recognize the clinical manifestations leading to the development and stage progression of diabetic nephropathy. - 1	Recognize the clinical manifestations leading to the development and stage progression of diabetic nephropathy. - NA
Utilize evolving therapeutic approaches to the treatment of diabetic nephropathy, including new diabetes drugs, dialysis and kidney transplantation.	Utilize evolving therapeutic approaches to the treatment of diabetic nephropathy, including new diabetes drugs, dialysis and kidney transplantation. - 5	Utilize evolving therapeutic approaches to the treatment of diabetic nephropathy, including new diabetes drugs, dialysis and kidney transplantation. - 4	Utilize evolving therapeutic approaches to the treatment of diabetic nephropathy, including new diabetes drugs, dialysis and kidney transplantation. - 3	Utilize evolving therapeutic approaches to the treatment of diabetic nephropathy, including new diabetes drugs, dialysis and kidney transplantation. - 2	Utilize evolving therapeutic approaches to the treatment of diabetic nephropathy, including new diabetes drugs, dialysis and kidney transplantation. - 1	Utilize evolving therapeutic approaches to the treatment of diabetic nephropathy, including new diabetes drugs, dialysis and kidney transplantation. - NA
Recognize the importance of determining glycemic goals due to the catastrophic consequences in the elderly population.	Recognize the importance of determining glycemic goals due to the catastrophic consequences in the elderly population. - 5	Recognize the importance of determining glycemic goals due to the catastrophic consequences in the elderly population. - 4	Recognize the importance of determining glycemic goals due to the catastrophic consequences in the elderly population. - 3	Recognize the importance of determining glycemic goals due to the catastrophic consequences in the elderly population. - 2	Recognize the importance of determining glycemic goals due to the catastrophic consequences in the elderly population. - 1	Recognize the importance of determining glycemic goals due to the catastrophic consequences in the elderly population. - NA
Appropriately select and use oral agents in the treatment elderly patients with diabetes.	Appropriately select and use oral agents in the treatment elderly patients with diabetes. - 5	Appropriately select and use oral agents in the treatment elderly patients with diabetes. - 4	Appropriately select and use oral agents in the treatment elderly patients with diabetes. - 3	Appropriately select and use oral agents in the treatment elderly patients with diabetes. - 2	Appropriately select and use oral agents in the treatment elderly patients with diabetes. - 1	Appropriately select and use oral agents in the treatment elderly patients with diabetes. - NA
Determine when and how to start insulin therapy in elderly populations with diabetes.	Determine when and how to start insulin therapy in elderly populations with diabetes. - 5	Determine when and how to start insulin therapy in elderly populations with diabetes. - 4	Determine when and how to start insulin therapy in elderly populations with diabetes. - 3	Determine when and how to start insulin therapy in elderly populations with diabetes. - 2	Determine when and how to start insulin therapy in elderly populations with diabetes. - 1	Determine when and how to start insulin therapy in elderly populations with diabetes. - NA
Evaluate the excess risk of CVD associated with DM compared to non-diabetic patients.	Evaluate the excess risk of CVD associated with DM compared to non-diabetic patients. - 5	Evaluate the excess risk of CVD associated with DM compared to non-diabetic patients. - 4	Evaluate the excess risk of CVD associated with DM compared to non-diabetic patients. - 3	Evaluate the excess risk of CVD associated with DM compared to non-diabetic patients. - 2	Evaluate the excess risk of CVD associated with DM compared to non-diabetic patients. - 1	Evaluate the excess risk of CVD associated with DM compared to non-diabetic patients. - NA
Evaluate the evidence that the use of SGLT2 inhibitors and GLP-1 agonists in diabetic patients is associated with the reduction of CVD.	Evaluate the evidence that the use of SGLT2 inhibitors and GLP-1 agonists in diabetic patients is associated with the reduction of CVD. - 5	Evaluate the evidence that the use of SGLT2 inhibitors and GLP-1 agonists in diabetic patients is associated with the reduction of CVD. - 4	Evaluate the evidence that the use of SGLT2 inhibitors and GLP-1 agonists in diabetic patients is associated with the reduction of CVD. - 3	Evaluate the evidence that the use of SGLT2 inhibitors and GLP-1 agonists in diabetic patients is associated with the reduction of CVD. - 2	Evaluate the evidence that the use of SGLT2 inhibitors and GLP-1 agonists in diabetic patients is associated with the reduction of CVD. - 1	Evaluate the evidence that the use of SGLT2 inhibitors and GLP-1 agonists in diabetic patients is associated with the reduction of CVD. - NA
Describe the mechanisms of action for the reduction of CVD with SGLT2 inhibitors and GLP-1 agonists and the lack of relationship to reduction in A1C.	Describe the mechanisms of action for the reduction of CVD with SGLT2 inhibitors and GLP-1 agonists and the lack of relationship to reduction in A1C. - 5	Describe the mechanisms of action for the reduction of CVD with SGLT2 inhibitors and GLP-1 agonists and the lack of relationship to reduction in A1C. - 4	Describe the mechanisms of action for the reduction of CVD with SGLT2 inhibitors and GLP-1 agonists and the lack of relationship to reduction in A1C. - 3	Describe the mechanisms of action for the reduction of CVD with SGLT2 inhibitors and GLP-1 agonists and the lack of relationship to reduction in A1C. - 2	Describe the mechanisms of action for the reduction of CVD with SGLT2 inhibitors and GLP-1 agonists and the lack of relationship to reduction in A1C. - 1	Describe the mechanisms of action for the reduction of CVD with SGLT2 inhibitors and GLP-1 agonists and the lack of relationship to reduction in A1C. - NA

How effective were the following speakers in meeting their learning objectives? *

Scoring key: 5=Very effective, 4= Effective, 3= Somewhat effective, 2= Slightly effective, 1= Completely Ineffective, NA=Not Applicable Speakers are listed according to the lecture schedule.

	5	4	3	2	1	NA
Erectile Dysfunction in Diabetic Men - Ranjith Ramasamy, M.D.	Erectile Dysfunction in Diabetic Men - Ranjith Ramasamy, M.D. - 5	Erectile Dysfunction in Diabetic Men - Ranjith Ramasamy, M.D. - 4	Erectile Dysfunction in Diabetic Men - Ranjith Ramasamy, M.D. - 3	Erectile Dysfunction in Diabetic Men - Ranjith Ramasamy, M.D. - 2	Erectile Dysfunction in Diabetic Men - Ranjith Ramasamy, M.D. - 1	Erectile Dysfunction in Diabetic Men - Ranjith Ramasamy, M.D. - NA
Advances in the Management of Diabetes in the Hospital Setting: Use of Oral Agents - Guillermo Umpierrez, M.D.	Advances in the Management of Diabetes in the Hospital Setting: Use of Oral Agents - Guillermo Umpierrez, M.D. - 5	Advances in the Management of Diabetes in the Hospital Setting: Use of Oral Agents - Guillermo Umpierrez, M.D. - 4	Advances in the Management of Diabetes in the Hospital Setting: Use of Oral Agents - Guillermo Umpierrez, M.D. - 3	Advances in the Management of Diabetes in the Hospital Setting: Use of Oral Agents - Guillermo Umpierrez, M.D. - 2	Advances in the Management of Diabetes in the Hospital Setting: Use of Oral Agents - Guillermo Umpierrez, M.D. - 1	Advances in the Management of Diabetes in the Hospital Setting: Use of Oral Agents - Guillermo Umpierrez, M.D. - NA
The Diabetic Heart - Theodore Feldman, M.D.	The Diabetic Heart - Theodore Feldman, M.D. - 5	The Diabetic Heart - Theodore Feldman, M.D. - 4	The Diabetic Heart - Theodore Feldman, M.D. - 3	The Diabetic Heart - Theodore Feldman, M.D. - 2	The Diabetic Heart - Theodore Feldman, M.D. - 1	The Diabetic Heart - Theodore Feldman, M.D. - NA
Diabetic Nephropathy - Gaspar Alejandro Barreto-Torrella M.D.	Diabetic Nephropathy - Gaspar Alejandro Barreto-Torrella M.D. - 5	Diabetic Nephropathy - Gaspar Alejandro Barreto-Torrella M.D. - 4	Diabetic Nephropathy - Gaspar Alejandro Barreto-Torrella M.D. - 3	Diabetic Nephropathy - Gaspar Alejandro Barreto-Torrella M.D. - 2	Diabetic Nephropathy - Gaspar Alejandro Barreto-Torrella M.D. - 1	Diabetic Nephropathy - Gaspar Alejandro Barreto-Torrella M.D. - NA
Management of Diabetes in the Elderly Patient - Guillermo Umpierrez, M.D., CDE	Management of Diabetes in the Elderly Patient - Guillermo Umpierrez, M.D., CDE - 5	Management of Diabetes in the Elderly Patient - Guillermo Umpierrez, M.D., CDE - 4	Management of Diabetes in the Elderly Patient - Guillermo Umpierrez, M.D., CDE - 3	Management of Diabetes in the Elderly Patient - Guillermo Umpierrez, M.D., CDE - 2	Management of Diabetes in the Elderly Patient - Guillermo Umpierrez, M.D., CDE - 1	Management of Diabetes in the Elderly Patient - Guillermo Umpierrez, M.D., CDE - NA
Diabetes and CV Outcomes - Theodore Feldman, M.D.	Diabetes and CV Outcomes - Theodore Feldman, M.D. - 5	Diabetes and CV Outcomes - Theodore Feldman, M.D. - 4	Diabetes and CV Outcomes - Theodore Feldman, M.D. - 3	Diabetes and CV Outcomes - Theodore Feldman, M.D. - 2	Diabetes and CV Outcomes - Theodore Feldman, M.D. - 1	Diabetes and CV Outcomes - Theodore Feldman, M.D. - NA

Was this course fair, balanced and without commercial bias? *

Yes

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

1-5

6-10

Over 10

Not applicable to my practice

Is this your first time attending this symposium? *

Yes

How did you hear about us? *

Would you attend this symposium again next year? *

Yes

If you checked "No,” please tell us why: *

If you checked "No,” please explain why you would not recommend this course: *

Please list specific changes you intend to implement in your daily practice as a result of attending this activity. *

If you do not plan to implement any new strategies learned, please list any barriers or obstacles that might keep you from doing so.

Suggested topics and/or speakers you would like for future symposiums.

Comments

Name

Leave this field blank

You are here

Diabetes Symposium Evaluation - October 13, 2018